Skip to main content
NNNN logo

Anbio Biotechnology

NNNNNASDAQHealthcareMedical Instruments & Supplies

$3.70Today:- (-)1Y −84.99%

As of Oct 26, 2026 close

Market cap
$162.40M
P/E (TTM)
23.52
Forward P/E
-
Dividend yield
-
52-week range
$3.09$44.73
Volume (live)
-
Avg. volume (3M)
119.60K

Anbio Biotechnology (NNNN) Cash Flow Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), Anbio Biotechnology used $6.74M of cash in operating activities. Free cash flow was −$6.74M.

Anbio Biotechnology Cash Flow Statement Analysis

Values in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Anbio Biotechnology (NNNN) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Operating Activities
Net Income6.402.372.2510.012.54
Depreciation & Amortization0.000.000.010.010.00
Change in Working Capital-13.210.04-1.20-5.531.65
Change in Accounts Receivable-2.590.82-1.880.72-0.72
Change in Inventory0.000.000.35-0.350.00
Change in Accounts Payable-1.630.80-0.58-0.481.89
Change in Other Working Capital-8.98-1.510.910.00-0.02
Other Operating Activities0.07-0.34-0.160.000.00
Net Cash from Operating Activities-6.742.080.904.454.18
Investing Activities
Capital Expenditures0.000.000.000.000.00
Purchases of Investments-19.42-35.47-18.54-16.090.00
Sales/Maturities of Investments15.2235.8020.2714.560.00
Net Cash from Investing Activities-4.200.341.73-1.530.00
Financing Activities
Common Stock Issued7.230.000.000.000.00
Other Financing Activities-0.28-0.34-0.040.000.00
Net Cash from Financing Activities6.95-0.34-0.040.000.00
Summary
Net Change in Cash-3.992.072.592.924.18
Cash at Beginning of Period11.769.697.104.180.00
Cash at End of Period7.7711.769.697.104.18
Free Cash Flow-6.742.080.904.454.18

Source: Company financial statements from annual and quarterly filings. Data as of Dec 31, 2025. Data sources and methodology

Frequently Asked Questions About Anbio Biotechnology Cash Flow

What is Anbio Biotechnology's free cash flow?

Anbio Biotechnology had negative free cash flow of $6.74M in fiscal 2025 (fiscal year ended Dec 31, 2025).

Does Anbio Biotechnology pay dividends or buy back shares?

Anbio Biotechnology's cash flow statement for fiscal 2025 shows no dividend payments or share repurchases.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition